Clinical Guides
Tinea Infections
A clinically focused guide to recognising and treating dermatophyte infections by site and extent, avoiding steroid-modified disease, and adapting safe prescribing and referral decisions to Indian practice. It separates clinical, mycological and cosmetic outcomes, highlights resistance, reservoirs, follow-up, pregnancy, hepatic risk, interactions and access, and is intended for supervised education rather than patient-specific prescribing. It supports safe counselling and practical follow-up.
MedNext Academy | 12 min read
Tinea Infections
A clinically focused guide to recognising and treating dermatophyte infections by site and extent, avoiding steroid-modified disease, and adapting safe prescribing and referral decisions to Indian practice. It separates clinical, mycological and cosmetic outcomes, highlights resistance, reservoirs, follow-up, pregnancy, hepatic risk, interactions and access, and is intended for supervised education rather than patient-specific prescribing. It supports safe counselling and practical follow-up.
Summary
Tinea is infection of keratinised skin, hair or nails by dermatophytes. Tinea corporis, cruris, pedis, faciei, capitis and unguium are clinical patterns, not interchangeable diagnoses. The advancing scaly edge, itch, exposure history and site can suggest the diagnosis, but eczema, psoriasis, candidiasis, erythrasma, scabies, seborrhoeic dermatitis and bacterial infection can look similar. A steroid-modified eruption may lose its ring and become widespread, inflamed or atypical. Confirm difficult, recurrent, extensive or treatment-resistant disease rather than repeatedly changing creams.
Treatment is selected by site, area, inflammation, hair or nail involvement, host factors and prior therapy. Localised uncomplicated glabrous tinea usually responds to a topical antifungal used correctly for the labelled course and beyond the visible edge. Multiple sites, extensive disease, recurrence, chronicity, failed topical therapy, scalp or nail infection and immunocompromise often require systemic treatment with specialist oversight. Do not use topical corticosteroid alone or fixed steroid-antifungal-antibacterial combinations as routine tinea treatment.
In India, recurrent and recalcitrant dermatophytosis and terbinafine-resistant Trichophyton indotineae are important considerations. Adherence, household and footwear measures, diabetes control and examination for reservoirs matter. Liver disease, interacting medicines, pregnancy, breastfeeding and childhood alter systemic choices. A lesion may remain darker or lighter after fungal clearance; pigment change alone is not treatment failure. This educational draft is reviewed and has been reviewed by the MedNext Clinical Team.
How Common Is It?
Dermatophyte infection is common worldwide and occurs in all age groups. Warmth, humidity, occlusive footwear, sweating, crowding and shared bathing facilities increase opportunity for transmission. The burden is not simply cosmetic: painful fissures, cellulitis, sleep disturbance, occupational limitation and secondary bacterial infection may follow. Tinea pedis can maintain infection elsewhere, and nail disease may act as a persistent reservoir.
Indian outpatient practice has seen a substantial burden of chronic, recurrent, steroid-modified and extensive glabrous dermatophytosis. This reflects climate, household spread, self-medication, easy access to combination creams, delayed diagnosis, variable drug quality and incomplete courses; it should not be reduced to a single behavioural explanation. The national prevalence is difficult to estimate because community surveys, clinical definitions and laboratory confirmation vary.
Ask about occupation, sports, hostel or barracks living, family members with itch, pets, shared towels, salons, footwear and previous pharmacy medicines. Record the anatomical sites and approximate body surface area rather than writing only “fungal infection”. Repeated relapse after apparently adequate therapy should prompt a search for untreated contacts, nails or feet, wrong diagnosis, steroid suppression, inadequate application, reinfection or resistance.
Risk Factors
Risk rises with sweating, friction, maceration, occlusive clothing or shoes, communal floors, contact sports, household exposure and animal contact. Diabetes, obesity, peripheral vascular disease, immunosuppression, HIV, atopic skin, chronic oedema and repeated skin trauma can increase persistence or complications. Children are particularly vulnerable to tinea capitis through close contact and shared combs, caps or bedding.
Drug and care factors are also risks. Potent topical corticosteroids can suppress inflammation while fungi continue to spread, producing tinea incognito. Irrational fixed combinations may contain a corticosteroid, antibacterial and antifungal in unequal or inappropriate doses. Stopping topical treatment as soon as itch improves, applying too little, or treating only the centre of a lesion encourages apparent failure. A nail or scalp reservoir can make skin treatment look unsuccessful.
Before systemic therapy, clarify liver disease, alcohol use, pregnancy or pregnancy plans, breastfeeding, renal illness, psoriasis or autoimmune disease, and all prescription, over-the-counter and herbal medicines. Review prior azole or terbinafine exposure and duration. Immunocompromise, extensive inflammation, pustules, nodules, facial or genital disease and possible bacterial superinfection lower the threshold for confirmation and referral.
Diagnosis
History
Ask when the eruption began, how it spread, itch or pain, recurrence, previous treatment and the exact response. Identify contacts, pets, communal bathing, sports, occupation, sweating, footwear and occlusion. Ask about scalp scaling, broken hairs, alopecia, kerion-like tenderness, nail change, diabetes, immunosuppression and fever. Establish whether a steroid or combination cream was used, its name if possible, frequency, duration and whether lesions rebound on stopping.
Examination
Inspect all likely reservoirs: trunk, groin, feet, interdigital spaces, nails, scalp and household-contact sites. Describe annular plaques, peripheral scale, central clearing, vesicles, pustules, fissures, erosions, follicular papules, nodules, alopecia and lymphadenopathy. Examine mucosa and genital skin sensitively. Tinea incognito may show poorly demarcated erythema, pustules or extensive plaques without a classic edge. Check for cellulitis, abscess, kerion and systemic illness.
Investigations
A potassium hydroxide (KOH) mount from active scale, taken from the advancing border after avoiding topical medicine where practical, can demonstrate hyphae in diagnostically difficult cases. Fungal culture helps identify species and guide therapy in recurrent, extensive or resistant disease; susceptibility testing may be needed where available. Nail disease needs mycological confirmation before prolonged oral treatment because trauma and psoriasis mimic it. Scalp infection generally needs microscopy and/or culture according to local service. Consider bacterial culture for purulence and glucose or immune evaluation when clinically indicated. A negative test does not end reasoning if sampling was poor; reassess the diagnosis and repeat or refer rather than escalating blindly.
Differential Diagnosis
Annular eczema, psoriasis, pityriasis rosea, granuloma annulare, subacute cutaneous lupus, fixed drug eruption and erythema annulare centrifugum may resemble tinea corporis. In the groin consider candidal intertrigo, erythrasma, inverse psoriasis and irritant dermatitis; erythrasma may fluoresce coral-red under Wood lamp. Foot scaling may be eczema, contact dermatitis, scabies or keratolysis. Facial lesions can be seborrhoeic dermatitis, rosacea, lupus or impetigo.
Follicular pustules or nodules raise Majocchi granuloma, bacterial folliculitis or inflammatory dermatoses and usually need microscopy, culture and specialist management. Scalp scaling with alopecia may be tinea capitis, alopecia areata, psoriasis, trichotillomania or bacterial infection. Thick dystrophic nails may be onychomycosis, psoriasis, lichen planus, trauma or melanoma.
Failure of a correctly applied antifungal is not proof of resistance. Check diagnosis, site, application, duration, adherence, reinfection and steroid exposure. In India, widespread recurrent disease with reduced response to terbinafine should raise concern for resistant dermatophyte, especially T. indotineae, but treatment should be guided by dermatology and mycology where possible. Do not treat every itch empirically with repeated oral antifungals.
Management
For a small number of uncomplicated glabrous lesions, use one appropriate topical antifungal such as terbinafine or an azole, applying to the lesion and a margin of normal skin according to the product label. Continue for the recommended duration and commonly for about two weeks after clinical resolution when advised by local guidance. Cream, lotion or spray is a practical choice by site; antifungal soaps are not a substitute. Keep skin dry, change damp clothes and socks, dry between toes, avoid sharing towels or clothing, and clean or rotate footwear. Treat tinea pedis and inspect nails when recurrent disease is present.
Systemic therapy is considered for extensive or multiple-site disease, chronic or recurrent infection, steroid-modified tinea, failure of an adequate topical course, scalp or nail involvement, inflammatory follicular disease and immunocompromise. IADVL/ITART describes terbinafine or itraconazole as options, often with topical treatment, but duration and dose must be individualised and prescribed by a qualified clinician. Do not extrapolate adult regimens to children or assume a longer course is automatically better. Review response, adherence, toxicity and the diagnosis.
Reduce reinfection by examining symptomatic household members and sharing practical hygiene advice without stigma. Diabetes and immunosuppression should be addressed. A persistent nodule, kerion, nail involvement, extensive facial or genital disease, or no meaningful improvement after a documented course deserves specialist review and possible culture or susceptibility testing.
Prescribing Information
Topical antifungals are generally safer than systemic treatment, but irritation, allergy and wrong-site use occur. Avoid corticosteroid monotherapy and routine steroid-antifungal combinations: they can mask tinea, enlarge the burden and cause atrophy, striae, acneiform change or systemic steroid effects. If a patient has been using a potent steroid, explain that the rash may change while the infection is treated and review rather than advising abrupt unsupervised manipulation of prolonged steroid use.
Oral terbinafine is hepatically metabolised and may cause gastrointestinal symptoms, rash, taste or smell disturbance and rare serious liver injury. Itraconazole has important CYP3A4 interactions, absorption issues and cardiac or hepatic precautions. Review medicines such as anticoagulants, statins, antiarrhythmics, anticonvulsants, immunosuppressants and acid-suppressing drugs before prescribing. Baseline liver assessment is prudent for systemic courses and repeat testing is guided by duration, risk and symptoms. Stop and seek urgent review for jaundice, dark urine, pale stools, severe rash or systemic illness.
Systemic antifungals require extra caution in pregnancy, breastfeeding, liver disease, children and frail older adults. Confirm the indication and seek dermatology or obstetric advice rather than relying on pharmacy combinations. Explain dose, duration, expected time to colour or nail normalisation, missed doses and follow-up. Do not share medicines, use leftover tablets or escalate a dose for “resistance” without specialist assessment.
When to Refer
Refer urgently for rapidly spreading erythema with fever, severe pain out of proportion, necrosis, abscess, facial or orbital involvement, dehydration, sepsis, or cellulitis in a high-risk diabetic or immunocompromised patient. Tinea capitis with kerion, extensive boggy inflammation, significant alopecia or suspected bacterial superinfection needs prompt paediatric or dermatology care because topical therapy alone is inadequate and scarring alopecia is possible.
Arrange dermatology or medical review for extensive or multiple-site disease, recurrent or chronic infection, steroid-modified tinea, Majocchi granuloma, nail involvement, genital or facial disease, pregnancy, significant liver disease, interacting medicines, immunosuppression, childhood disease or treatment failure. Send prior treatment names and dates, photographs where consented, KOH/culture results and comorbidity information.
Refer suspected resistant infection for species identification and susceptibility testing where feasible, particularly after appropriate adherence and diagnosis have been checked. Referral pathways differ across India; a district hospital, medical college dermatology service or teledermatology consultation may be appropriate. Avoid serial empiric oral antifungals while waiting. A referral should state the clinical pattern, extent, prior steroid exposure, systemic medicines and the specific question requiring specialist input.
Red Flags
Emergency assessment is needed for fever or toxicity with rapidly progressive skin inflammation, severe pain, bullae, necrosis, lymphangitis, facial swelling, orbital symptoms or airway compromise. Purulence, fluctuance or extensive cellulitis may indicate bacterial infection needing drainage or antibiotics rather than more antifungal cream. Immunocompromised and diabetic patients can deteriorate with less dramatic local signs.
Scalp tenderness, boggy swelling, pus, cervical nodes and broken hairs suggest kerion; delay risks permanent scarring alopecia. Painful nodules or pustules within a tinea plaque may indicate Majocchi granuloma. A black, irregular or changing nail lesion needs assessment for melanoma rather than an assumption of fungus.
During systemic treatment, jaundice, dark urine, severe nausea, widespread blistering or mucosal ulceration, facial oedema, breathing difficulty or a rapidly spreading rash are urgent adverse-event signals. Recurrent disease despite documented adherence, new lesions while on therapy, or persistent inflammation after adequate treatment requires diagnostic review. Do not repeatedly add corticosteroids to suppress an unexplained eruption.
Indian Clinical Context
India has a high clinical burden of dermatophytosis, including chronic, recurrent, extensive and steroid-modified presentations. IADVL/ITART consensus strongly discourages topical corticosteroids, including combination products, and supports KOH examination when clinical diagnosis is difficult. Local practice should account for the accessibility of microscopy, culture, dermatology expertise and reliable follow-up. A pharmacy purchase is not equivalent to a confirmed diagnosis.
Terbinafine-resistant T. indotineae and reduced response in recalcitrant disease are important concerns, but resistance should not be presumed from a single early review. Verify application, duration, adherence, reinfection, steroid exposure, nail or scalp reservoirs and alternative diagnoses. If the pattern remains resistant, seek mycology or dermatology input and use susceptibility-informed treatment where available.
Counselling should be realistic and affordable: dry folds and feet, wash and dry clothing, do not share towels, wear breathable footwear, and treat symptomatic contacts. Avoid blaming patients who used over-the-counter combinations; explain why stopping harmful steroid exposure and completing an appropriate plan matters. Consider diabetes, anaemia, HIV risk with consent, immunosuppressive therapy, pregnancy, drug access and travel distance when arranging monitoring. Never provide patient-specific dosing through this general educational guide.
A local clinician should also consider whether the patient can return for liver-test review, whether a trustworthy pharmacy can supply the same medicine, and whether cost will interrupt therapy. Explain that clearing scale and itch can precede normal skin colour, while nail or hair recovery takes much longer. Use interpreters where needed and document consent before photographing lesions.
NMC Competency Mapping
This topic supports NMC CBME learning across dermatology, microbiology, pharmacology, medicine, paediatrics and AETCOM. At Know level, learners should classify tinea by anatomical site, describe dermatophyte infection of keratin, recognise the advancing scaly edge and list common mimics. They should know that steroids can alter morphology and that scalp and nail disease usually require systemic or specialist management.
At Know How level, learners should take an exposure and medicine history, examine reservoirs, choose KOH microscopy or culture when appropriate, and distinguish localised disease suitable for topical treatment from extensive, recurrent or hair/nail disease requiring referral. They should explain why fixed steroid combinations are unsafe, identify liver and interaction risks, and use antimicrobial and antifungal stewardship principles.
At Show How level, a learner can counsel a patient on cream application, footwear and household measures; demonstrate a focused skin, scalp and nail examination; interpret a KOH result in context; and safety-net a kerion or cellulitis. Prescribing systemic antifungals, sampling, paediatric treatment and resistant-infection management remain supervised clinical acts under institutional policy. Communication should acknowledge stigma, cost, privacy and uncertainty rather than promise a guaranteed cure.
Key Exam Pearls for NEET PG
Dermatophytes infect keratinised tissue; tinea corporis often has peripheral scale with central clearing, but steroid-modified disease may be atypical. KOH from the active edge can show branching septate hyphae. Tinea capitis needs systemic therapy because topical agents do not reliably penetrate hair shafts; kerion can scar. Onychomycosis should be confirmed before prolonged oral treatment because psoriasis and trauma mimic it.
Topical corticosteroid alone or steroid-antifungal combinations can create tinea incognito and should be avoided. Limited uncomplicated skin disease is usually managed with a topical antifungal; multiple sites, extensive, chronic, recurrent, steroid-modified, scalp, nail or immunocompromised disease may need oral therapy. Terbinafine and itraconazole have different interaction and hepatic considerations.
In Indian practice, recurrent disease and T. indotineae resistance require attention to adherence, reinfection, culture and specialist review. Treat reservoirs such as feet and nails, keep folds dry and avoid shared towels. Red flags include kerion, cellulitis, severe drug reaction and systemic illness. Exam answers must separate diagnosis, site-specific treatment, safety monitoring and stewardship rather than naming one universal antifungal. Also remember that post-inflammatory pigment can persist after mycological cure, and that a persistent nail dystrophy is not evidence of active infection without appropriate testing. A safe answer states when to sample, when to refer, and which medicine hazards must be checked before prescribing.
Frequently Asked Questions
Should every ring-shaped rash be treated as tinea?
No. The shape is suggestive but not diagnostic. Eczema, psoriasis, pityriasis rosea, granuloma annulare, candidiasis and other conditions may be annular. Examine the active edge and likely reservoirs, review steroid or combination-cream exposure, and use KOH microscopy when the appearance is atypical, recurrent, extensive or not responding. Repeated empiric oral antifungals can cause harm and delay the correct diagnosis. Ask whether pigment change is being mistaken for active fungus and whether a nail or foot reservoir is causing genuine relapse. Document the examination and treatment timeline, including any prior steroid use and exact application sites.
Why are steroid combination creams a problem in Indian tinea?
A potent corticosteroid can reduce redness and itch while the dermatophyte continues to grow. The eruption may spread, lose its ring, recur after temporary improvement and become difficult to recognise. Combination products may also contain unnecessary antibacterial ingredients. IADVL consensus discourages topical corticosteroids alone or combined with antifungals for glabrous tinea. A clinician should review prolonged use, confirm the diagnosis and give a simple antifungal plan with follow-up.
When is an oral antifungal needed?
Oral treatment is considered for scalp or nail infection, extensive or multiple-site disease, chronic or recurrent infection, steroid-modified disease, follicular or Majocchi infection, failed adequate topical treatment or immunocompromise. The choice and duration depend on site, organism, age, pregnancy, liver disease and interactions. Confirm difficult disease and obtain specialist advice; do not self-start leftover tablets or increase a dose because improvement is slow.
What should someone do if tinea keeps returning?
First check that the diagnosis is correct, the cream reached beyond the visible margin, the full course was completed and steroid exposure stopped. Examine feet, nails and scalp for reservoirs and ask about household contacts, pets, towels, footwear and sweating. Diabetes or immunosuppression may need attention. If disease remains widespread or unresponsive, dermatology review with KOH, culture and susceptibility testing can identify resistant dermatophytes or a mimic.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic